Senior Director, Technical Program Design in the Commercial Operations team for Viral Vector Services, Thermo Fisher Scientific
Susan D’Costa is currently the Sr. Director, Technical Program Design in the Commercial Operations team for Viral Vector Services, Thermo Fisher Scientific. In this role, she functions as SME for VVS’ viral vector manufacturing platforms and systems providing scientific and technical input for customer programs. Prior to this role, she served as the Head of Process and Analytical Development at Viral Vector Services, Thermo Fisher Scientific, formerly Brammer Bio for over three years. In her role as head of PD/ADA, she provided critical scientific input for projects developed and manufactured at VVS. She has built a robust team for the development, customization, optimization, scale-up and tech transfer of gene therapy vector process and analytics. Susan was also integral to developing robust QC analytics for incoming starting and raw materials and for the release of the clinical vector products in her role as Director of Quality Control at Brammer Bio/Florida Biologix. She holds a Ph.D. in Molecular Virology and has over 20 years of experience in molecular virology.
M Delahaye,
Michael Delahaye
Head of Viral Vector Industrialization, Cell & Gene Therapy Catapult
Michael is the Head of Viral Vector Industrialisation at the Cell and Gene Therapy Catapult and has almost 15 years of industrial experience within the cell and gene therapy sector. He leads a team of experienced scientists within the Viral Gene Delivery programme, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. The team’s key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of AAV based gene therapies. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture
M DiBiasio-White et al.
Michael DiBiasio-White
Senior Scientist at Affinia Therapeutics
Michael J White, Senior Scientist at Affinia Therapeutics where he is leading the process development efforts focused on novel AAV vector variants. Before joining Affinia, Michael held roles at Ring therapeutics where he led teams focused on designing processes and developing novel viral vector technologies for Anelloviruses.
Senior Director, Technical Program Design in the Commercial Operations team for Viral Vector Services, Thermo Fisher Scientific
Susan D’Costa is currently the Sr. Director, Technical Program Design in the Commercial Operations team for Viral Vector Services, Thermo Fisher Scientific. In this role, she functions as SME for VVS’ viral vector manufacturing platforms and systems providing scientific and technical input for customer programs. Prior to this role, she served as the Head of Process and Analytical Development at Viral Vector Services, Thermo Fisher Scientific, formerly Brammer Bio for over three years. In her role as head of PD/ADA, she provided critical scientific input for projects developed and manufactured at VVS. She has built a robust team for the development, customization, optimization, scale-up and tech transfer of gene therapy vector process and analytics. Susan was also integral to developing robust QC analytics for incoming starting and raw materials and for the release of the clinical vector products in her role as Director of Quality Control at Brammer Bio/Florida Biologix. She holds a Ph.D. in Molecular Virology and has over 20 years of experience in molecular virology.
M Delahaye,
Michael Delahaye
Head of Viral Vector Industrialization, Cell & Gene Therapy Catapult
Michael is the Head of Viral Vector Industrialisation at the Cell and Gene Therapy Catapult and has almost 15 years of industrial experience within the cell and gene therapy sector. He leads a team of experienced scientists within the Viral Gene Delivery programme, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. The team’s key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of AAV based gene therapies. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture
M DiBiasio-White et al.
Michael DiBiasio-White
Senior Scientist at Affinia Therapeutics
Michael J White, Senior Scientist at Affinia Therapeutics where he is leading the process development efforts focused on novel AAV vector variants. Before joining Affinia, Michael held roles at Ring therapeutics where he led teams focused on designing processes and developing novel viral vector technologies for Anelloviruses.
Brijender Parsad has been involved with process control and automation field for over 25 years. Currently he is a Senior Manager, Corporate Engineering Group for Kite, a Gilead Company. Kite is singularly focused on cell therapy — the use of genetically modified immune cells programmed to target tumors. Previously he worked for Novartis, Dupont, Georgia Pacific and as a consultant in automation engineering for chemical, biotech and pharma industries.
Director in the Cell and Gene Therapy Technology group at Orchard Therapeutics in London
Suzanne Aldington is a Director in the Cell and Gene Therapy Technology group at Orchard Therapeutics in London, where she has worked since the beginning of 2020. Previously she was at Lonza, a Contract Manufacturer based in Slough, UK for 20 years. During this time her experience included purification process development, scale up activities at non GMP pilot scale and subsequent process transfers into GMP manufacturing facilities. In addition, she gained considerable experience in process validation including supporting multiple on site inspections by the FDA and other Health Agencies. She has over 30 years experience in academia and in the biotechnology industry. After completing a degree in Microbiology at Imperial College, she studied for a PhD in biochemical engineering at Birmingham University which included purification of an enzyme produced in microbial culture.
Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vineti. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.
Welcome back, please log in to access our articles, interviews, webinars and more
Welcome back, please log in to access our articles, interviews, webinars and more
If you would also like to sign up to access articles from Immuno-Oncology Insights - one of the other great titles from Bioinsights, please tick the box below.
As you are already a member of Immuno-Oncology Insights (also from Bioinsights), all you need to do is log in using your Immuno-Oncology password and tick the box below to become a member of Cell and Gene Therapy Insights.
Welcome back!
You are already a member of Cell and Gene Therapy Insights (from Bioinsights). If you would also like to become a member of Immuno-Oncology Insights , you can simply log in with your Cell and Gene Therapy Insights Insights password and tick the box below.
Welcome back!
You are already a member of Immuno-Oncology Insights (from Bioinsights).
If you would also like to become a member of Cell and Gene Therapy Insights, you can simply log in with your Immuno-Oncology Insights password and tick the box below.
